Product Overview

Trajenta Duo 2.5/850 Mg is a fixed‑dose combination tablet that unites the DPP‑4 inhibitor linagliptin with the biguanide metformin. It is produced by Boehringer Ingelheim India Pvt. Ltd., a subsidiary of the global Boehringer Ingelheim group, and is marketed for the management of type 2 diabetes mellitus. The product is supplied in foil‑sealed strips containing ten tablets each, and it is available in pack sizes of 30, 60, and 90 tablets to accommodate both short‑term and long‑term treatment regimens. Shipping typically takes between six and fifteen days, depending on the destination and the selected pack size. The tablets are film‑coated to protect the active ingredients from moisture and to ensure consistent release in the gastrointestinal tract. Each strip is individually numbered for traceability, and the packaging complies with Indian regulatory standards for pharmaceutical products. For more information about diabetes and its management, refer to the National Institutes of Health.

What is Trajenta Duo 2.5/850 Mg

Trajenta Duo 2.5/850 Mg combines two distinct pharmacological agents in a single dose. Linagliptin, a potent and long‑acting DPP‑4 inhibitor, enhances the activity of incretin hormones such as GLP‑1, which stimulate insulin secretion and suppress glucagon release after meals. Metformin, a widely used biguanide, reduces hepatic glucose production, improves peripheral insulin sensitivity, and modestly decreases intestinal glucose absorption. The fixed‑dose formulation delivers 2.5 mg of linagliptin alongside 850 mg of metformin per tablet, providing a convenient once‑daily option that simplifies the medication schedule for patients who would otherwise need to take separate pills. Because linagliptin is eliminated primarily through the gastrointestinal tract and has minimal renal clearance, it can be used in patients with mild to moderate kidney impairment without dose adjustment, whereas metformin requires cautious dose reduction when the estimated glomerular filtration rate falls below 45 mL/min/1.73 m².

Uses and Benefits

The primary therapeutic indication for Trajenta Duo 2.5/850 Mg is the improvement of glycemic control in adults with type 2 diabetes who have not achieved adequate glucose regulation through diet and exercise alone. Clinical studies have demonstrated that the combination leads to meaningful reductions in HbA1c, fasting plasma glucose, and post‑prandial glucose excursions, while maintaining a low risk of hypoglycemia when used without sulfonylureas or insulin. In addition, the metformin component contributes to modest weight neutrality and may favorably affect lipid profiles, offering cardiovascular benefits that are particularly relevant for patients with comorbid metabolic syndrome. Type 2 diabetes is a chronic condition characterized by insulin resistance; learn more at Wikipedia. The once‑daily dosing schedule also improves adherence, which is a key factor in long‑term disease management. Healthcare providers often consider this regimen for patients who require an initial pharmacologic step or for those transitioning from dual therapy with separate linagliptin and metformin tablets, as the combined product reduces pill burden and may enhance patient satisfaction.

How It Works

The antidiabetic effect of Trajenta Duo arises from the complementary mechanisms of its two constituents. Linagliptin binds irreversibly to the DPP‑4 enzyme, preventing the degradation of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release, thereby lowering blood glucose without causing excessive insulin release. Metformin, on the other hand, activates AMP‑activated protein kinase (AMPK) in liver and muscle cells, leading to decreased hepatic gluconeogenesis, increased peripheral glucose uptake, and improved insulin signaling. The simultaneous action of incretin potentiation and hepatic glucose suppression creates a synergistic glycemic lowering effect that is greater than the sum of each agent’s individual impact. Because linagliptin is not metabolized by cytochrome P450 enzymes, it has a low potential for drug‑drug interactions, making it suitable for patients on multiple chronic therapies.

Dosage Guidelines

The recommended initial dosage of Trajenta Duo 2.5/850 Mg is one tablet taken orally once daily, preferably with the morning meal to reduce gastrointestinal discomfort. Patients with normal renal function (eGFR ≥60 mL/min/1.73 m²) may continue this dose without modification. In individuals with moderate renal impairment (eGFR 45–59 mL/min/1.73 m²), the dose should be reduced to one tablet every other day, while those with severe renal impairment (eGFR <45 mL/min/1.73 m²) should avoid metformin and therefore may need an alternative therapy. If a dose is missed, the patient should take it as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped and treatment resumed at the regular interval. Adjustments are also advised when the medication is used in combination with other antidiabetic agents that increase the risk of hypoglycemia.

Side Effects

Most patients tolerate Trajenta Duo 2.5/850 Mg well, but like all medications it can cause adverse effects. The most frequently reported side effects include mild nausea, diarrhea, abdominal discomfort, and occasional metallic taste. In rare circumstances, the metformin component may be associated with lactic acidosis, especially in patients with compromised renal function, severe hepatic disease, or prolonged fasting states; immediate medical evaluation is required if unexplained muscle pain, rapid breathing, or dizziness occurs. Linagliptin is generally associated with a low incidence of hypoglycemia when used alone, yet the risk can increase when combined with sulfonylureas or insulin. Additionally, hypersensitivity reactions such as rash or angioedema, although uncommon, necessitate discontinuation of the drug and prompt clinical assessment. For detailed drug information, see Drugs.com. Patients should be instructed to report any persistent gastrointestinal symptoms or signs of allergic reaction to their healthcare provider, and laboratory monitoring may be recommended at intervals determined by the prescribing clinician.

Warnings and Precautions

Before initiating therapy with Trajenta Duo, clinicians should assess renal function, hepatic health, and history of pancreatitis, as these factors can influence the safety profile of the medication. Metformin is contraindicated in patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m² or in those who have experienced a significant metabolic derangement such as acute heart failure or septic shock. Caution is also advised in elderly patients, who may be more susceptible to dehydration and renal function decline. The drug should be discontinued prior to undergoing procedures that require intravascular contrast agents, and it should not be restarted until renal function has been re‑evaluated and found stable. Pregnant or lactating women should consult a physician before use, as the safety of linagliptin during pregnancy has not been fully established. Additional safety resources are available at the MedlinePlus website.

Frequently Asked Questions

• What is the recommended starting dose? The usual starting dose is one tablet daily, taken with food; dosage may be adjusted based on kidney function and physician guidance.
• Can Trajenta Duo be used together with other diabetes medicines? Yes, it can be combined with certain agents, but when used with drugs that increase hypoglycemia risk, dose adjustments may be necessary; see the prescribing information for details.
• Is the medication safe for patients with mild kidney disease? Linagliptin does not require dose adjustment in mild renal impairment, whereas metformin may need reduction; always check eGFR with your doctor before starting.
• How long does it take to see improvements in blood sugar levels? Glycemic control may begin to improve within one to two weeks, but the full effect is usually observed after several weeks of consistent use; for more evidence, refer to studies on PubMed.
• Where can I find the official prescribing information? Detailed FDA‑approved labeling and safety data are available at the FDA website and on Drugs.com.

Related Products

• Okamet 500 Mg (Metformin)
• Afatinib Dimaleate 20 mg (Generic)
• Afatinib Dimaleate 30 mg (Generic)
• Afatinib Dimaleate 40 mg (Generic)
• Afatinib Dimaleate 50 mg (Generic)
• Cyendiv 100 mg (Nintedanib)
• Cyendiv 150 mg (Nintedanib)
• Xovoltib (Afatinib Dimaleate)
• Xovoltib 20 mg (Afatinib Dimaleate)
• Xovoltib 30 mg (Afatinib Dimaleate)
• Xovoltib 40 mg (Afatinib Dimaleate)
• Xovoltib 50 mg (Afatinib Dimaleate)